Search

Displaying results 2261 - 2270 of 10000 in total
  1. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.

  2. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms. … contribute to the pathophysiology of Alzheimer's Disease (AD).

  3. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. … [A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions.

  4. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    [L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015] … Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have

  5. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    [L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and its associated sequelae on an individual patient can be debilitating. … [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines

  6. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    the use of baricitinib for the treatment of COVID-19 in May 2022. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.

  7. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction

  8. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

    Categories: Drugs for Treatment of Tuberculosis, Heterocyclic Compounds with 4 or More Rings
  9. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    Food and Drug Administration on August 1, 2017. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.

    Synonyms: 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol
  10. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … [zopiclone], [zolpidem], benzodiazepines) focus on enhancing sleep drive via modulation of GABA and melatonin receptors, lemborexant and other orexin antagonists (e.g.